Research Topics
| Joel RaskinSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studiesJonathan Davidson
Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
Hum Psychopharmacol 23:519-26. 2008..To assess the efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder (GAD)...
Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic featuresCraig H Mallinckrodt
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
BMC Psychiatry 5:1. 2005..Pooled data from double-blind, placebo-controlled studies were utilized to compare the efficacy of duloxetine in depressed patients with and without melancholic features...- The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trialsCraig H Mallinckrodt
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
BMC Psychiatry 4:26. 2004..We compared results from MMRM and LOCF_ANCOVA analyses across eight clinical trials of duloxetine in order to investigate how the choice of primary analysis may influence interpretations of efficacy... 
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trialJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, Ontario, Canada MIN 2E8
Am J Psychiatry 164:900-9. 2007..This study compared the effects of duloxetine, 60 mg/day, versus placebo on cognition, depression, and pain in elderly patients with recurrent major depressive disorder...- Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorderJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
J Clin Psychopharmacol 28:32-8. 2008..To compare the safety and tolerability profile of duloxetine versus placebo in elderly (> or = 65 years) patients with major depressive disorder (MDD)... - A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
Pain Med 6:346-56. 2005..Assess efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain (DPNP)... - Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety studyJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, Toronto, Canada
Pain Med 7:373-85. 2006..This study assessed the 6-month safety and tolerability of duloxetine in patients with DPNP; evaluation of efficacy was a secondary objective... - Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic painJoel Raskin
Lilly Research Laboratories, Toronto, Canada
J Palliat Med 9:29-40. 2006.... - Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopramJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Ave, Toronto, ON, Canada M1N 2E8
J Psychiatr Res 46:667-74. 2012..However, given the study limitations, it is possible that more specific targeting of the noradrenergic pathway would be of benefit... - Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorderJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
Int Psychogeriatr 20:309-27. 2008..Rapid response to antidepressant therapy is desirable and may be particularly critical in elderly patients with major depressive disorder (MDD)... - An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic painJoachim F Wernicke
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Pain Med 8:503-13. 2007..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)... - A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorderDavid G S Perahia
Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
J Psychiatr Res 42:22-34. 2008..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment... - Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?David G S Perahia
Lilly Research Centre, Windlesham, Surrey, UK
Int Clin Psychopharmacol 21:311-7. 2006.... - Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristicsDavid G S Perahia
Lilly Research Centre, Windlesham, Surrey, UK
Int Clin Psychopharmacol 21:285-95. 2006..Duloxetine was effective in the treatment of first and subsequent episodes of major depressive disorder, and regardless of duration of the current depressive episode... - Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritisMadelaine M Wohlreich
correspondence and M D, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4103, Indianapolis, IN 46285, USA
Psychosomatics 50:402-12. 2009.... - An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studiesJoachim Wernicke
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Drug Saf 30:437-55. 2007..This study was designed to evaluate the cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events (AEs)... - Duloxetine in the long-term treatment of major depressive disorderJoel Raskin
Lilly Research Laboratories, Eli Lilly Canada, 3650 Danforth Avenue, Scarborough, Ontario, Canada M1N 2E8
J Clin Psychiatry 64:1237-44. 2003..This clinical trial evaluated the long-term (1 year) safety and efficacy of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in patients with DSM-IV major depressive disorder... - Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studiesTina M Oakes
Eli Lilly and Company, Indianapolis, Indiana, USA
Int Clin Psychopharmacol 28:1-11. 2013..The incidence of abnormal low sodium levels was not significantly different between treatments. These safety results may better inform clinicians providing individualized care to elderly patients with major depressive disorder... - Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effectsSidney H Kennedy
Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario, Canada
J Clin Psychiatry 63:181-6. 2002..CONCLUSION: Bupropion had an effect on the pharmacokinetics of venlafaxine but not those of the SSRIs. Further investigation of combination treatments under randomized, double-blind conditions is recommended... - Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetineJohn Greist
Healthcare Technology Systems, Madison, Wisconsin 53717, USA
Clin Ther 26:1446-55. 2004..This analysis assessed the incidence, severity, onset, and duration of nausea among patients with major depressive disorder (MDD) treated with the new antidepressant duloxetine... - Management of depression relapse: re-initiation of duloxetine treatment or dose increaseMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, ACC 812, Boston, MA 02114, United States
J Psychiatr Res 40:328-36. 2006..Patients relapsing on duloxetine 60 mg QD benefited from an increase to 60 mg BID. These duloxetine doses were well tolerated and effective, and appear appropriate for MDD patients requiring treatment of relapse... - Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialMoira Rynn
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Depress Anxiety 25:182-9. 2008..Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD... - Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trialStephan Brecht
Boehringer Ingelheim GmbH, Ingelheim, Germany
J Clin Psychiatry 68:1707-16. 2007..This study evaluated the efficacy and safety of duloxetine in the treatment of patients with moderate pain associated with depression... - Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depressionRichard C Shelton
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Int Clin Psychopharmacol 22:348-55. 2007.... - Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and BrazilPhil Lee
Eli Lilly, Taipei, Taiwan
Psychiatry Clin Neurosci 61:295-307. 2007..The present study verifies the utility of duloxetine as an efficacious and safe treatment for both emotional and physical symptoms of MDD in this predominantly Asian patient sample... - Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trialsChrister Allgulander
Karolinska Institutet, Stockholm, Sweden
Curr Med Res Opin 23:1245-52. 2007..A pooled dataset from all completed trials is provided here to show the most likely clinical outcomes associated with duloxetine treatment for GAD... - Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studiesJean Endicott
New York State Psychiatric Institute and Columbia School of Medicine, New York, NY 10032, USA
J Clin Psychiatry 68:518-24. 2007..The present work examined the efficacy of duloxetine treatment for improving functional outcomes for patients with GAD in 3 independent clinical studies...